A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung cancer

摘要: BACKGROUND. A previous pilot study from our group suggested that : (1) adoptive immunotherapy (Al) with tumor-infiltrating lymphocytes (TIL) and recombinant interleukin-2 (rIL-2) may be applied safety to more than 80% of the patients who had surgery for Stage III nonsmall cell lung carcinoma (NSCLC) ; (2) AI could useful in locally advanced disease. The present randomized was planned assess efficacy postoperative treatment II, IIla, or IIIb NSCLC. METHODS. TIL were expanded vitro tissue samples obtained surgically removed specimens 131 patients. Eighteen cultures yielded no growth TIL. remaining 113 stratified according disease stage receive standard chemoradiotherapy. infused intravenously 6 8 weeks after surgery. rIL-2 administered subcutaneously at escalating doses 2 weeks, then reduced 3 months. RESULTS. Three-year survival significantly better (P < 0.05) underwent controls. Al benefit II NSCLC, potentially IIIa NSCLC = 0.06), advantageous (T4) 0.01). For local relapse (but not distant relapse) following 0.05). CONCLUSIONS. should considered when designing future adjuvant therapy protocols